Latest Conference Articles

Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability

Skylar Jeremias

April 30 2024

During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.

Adam Colborn Reviews Biosimilar Interchangeability Requirements, Advocates for Pharmacist Resources

Cameron Santoro

April 28 2024

In an interview with Adam Colborn, JD, director of government relations for the Academy of Managed Care Pharmacy focuses on biosimilar interchangeability and approaches to encourage wider adoption in dispensing these medications.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

Skylar Jeremias

April 24 2024

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

AON Saves Over $243 Million With High Biosimilar Adoption

Skylar Jeremias

April 22 2024

Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.

The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability

Skylar Jeremias

April 16 2024

Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.

AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars

Skylar Jeremias

March 20 2024

Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.

Posters From AMCCBS and AAD Showcase New Technology for Biosimilar Uptake, Barriers to Self-Injectable Biologics

Skylar Jeremias

March 14 2024

Posters from Association of Cancer Care Centers 50th Annual Meeting and Cancer Center Business Summit (AMCCBS) and the American Academy of Dermatology (AAD) highlight the benefits of incorporating biosimilars into electronic medical records and the biggest barriers for home injection of biologics.

Celltrion, Samsung Bioepis Unveil New Biosimilar Data in CD, UC at ECCO 2024

Skylar Jeremias

February 23 2024

At the Congress of European Crohn’s and Colitis Organisation (ECCO), Celltrion and Samsung Bioepis presented new finding from their respective biosimilar analyses, demonstrating positive safety and efficacy measures for the biosimilars as treatments for Crohn disease (CD) and ulcerative colitis (UC).

SABCS Posters Review Use of Biosimilars in New Contexts as Breast Cancer Therapy

Skylar Jeremias

January 17 2024

As one study presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) evaluated the use of circulating tumor DNA for response prediction after combination therapy with a trastuzumab biosimilar, another examined the efficacy of a pertuzumab biosimilar candidate.

Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape

Skylar Jeremias

January 14 2024

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.